Hodgkin Disease: all 914 studies
Page 1 of 10. Open to participants first (136), then studies with results posted, then the rest; newest registration first within each.
- Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced CardiotoxicityNot yet recruitingNCT07838649Phase 1
- Proton Therapy for Mediastinal Lymphoma (PROMLY)RecruitingNCT07817641Not applicable
- New Approaches for the Diagnosis of Lymphoma and Multicentric Castleman DiseaseRecruitingNCT07793006Not applicable
- Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)Not yet recruitingNCT07729397Phase 1
- Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic MalignanciesNot yet recruitingNCT07710781Not applicable
- PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's LympomaNot yet recruitingNCT07641010Phase 1/2
- A Phase I Study of JLM019 InjectionRecruitingNCT07623850Phase 1
- Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO TrialNot yet recruitingNCT07576725Phase 2
- Cord Blood Transplantation in Children and Young Adults With Blood CancerRecruitingNCT07566377Phase 2
- Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHLRecruitingNCT07551583Phase 2
- Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's LymphomaRecruitingNCT07514819Not applicable
- CD45BE-HSPC + CART-45 CellsRecruitingNCT07451054Phase 1
- Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid MalignanciesRecruitingNCT07444632Phase 1
- Halt Aging in Survivors of Blood CancersRecruitingNCT07292272Not applicable
- The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruitingNCT07285044Phase 2
- Genetic Markers of Susceptibility to Chemotherapy-induced Ovarian Damage in Cancer Patients Undergoing Ovarian Biopsy for Cryopreservation.RecruitingNCT07270679
- PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin LymphomaRecruitingNCT07256158Phase 3
- Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHLRecruitingNCT07234487Phase 2
- Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin LymphomaRecruitingNCT07222345Not applicable
- PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin LymphomaRecruitingNCT07209059Phase 2
- Mozobil for Autologous Hematopoietic Stem Cell TransplantationRecruitingNCT07188090Phase 2
- Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin LymphomaNot yet recruitingNCT07164469Phase 2
- ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT07021989Phase 2
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell TransplantRecruitingNCT07020533Phase 1
- BrECADD Therapy in Stage 2 B-IV Hodgkin LymphomaRecruitingNCT07002216Phase 2
- Nivo40-AVD for Advanced Classic Hodgkin LymphomaRecruitingNCT06984146Phase 2
- Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab TreatmentEnrolling by invitationNCT06931613Phase 2
- Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND TrialRecruitingNCT06923397Not applicable
- Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin LymphomaNot yet recruitingNCT06919679Phase 2
- Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin LymphomaNot yet recruitingNCT06916416Phase 2
- A Study of Carmustine With and Without Ethanol in Subjects With LymphomaRecruitingNCT06915246Phase 2
- Clinical Investigation of Proton Treatment in Hodgkin Lymphoma Patients - PRO-HodgkinRecruitingNCT06883604Not applicable
- Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: a Phase II StudyRecruitingNCT06848569Phase 2
- A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in IndiaRecruitingNCT06831370Phase 4
- PD-1 Inhibitors Maintenance for cHL Post-autoHCTRecruitingNCT06812858Phase 2
- Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With AnthracyclinesRecruitingNCT06774326
- BV in the Treatment of Relapsed/refractory Hodgkin LymphomaNot yet recruitingNCT06761911Phase 4
- Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's LymphomaRecruitingNCT06761274Not applicable
- Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced LymphomaRecruitingNCT06755450Phase 1
- Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's LymphomaRecruitingNCT06733987
- Atorvaststin and Cardiotoxicity in Acute Myloid LeukemiaNot yet recruitingNCT06684509Phase 1/2
- A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin LymphomaRecruitingNCT06642792Phase 1/2
- Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot TrialRecruitingNCT06580002Phase 2
- A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell LymphomaRecruitingNCT06494371Phase 1
- An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced TumorsRecruitingNCT06487624Phase 1
- A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHLRecruitingNCT06484920Phase 2
- A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin LymphomaNot yet recruitingNCT06465446Phase 3
- Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma SurvivorsRecruitingNCT06421987
- Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingNCT06398457Early Phase 1
- Wisconsin Ginseng for Decreasing Cancer Related FatigueRecruitingNCT06395441Phase 3
- A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.RecruitingNCT06383338Phase 1
- A Study of BV-AVD in People With Bulky Hodgkin LymphomaRecruitingNCT06377566Phase 2
- Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid TumoursNot yet recruitingNCT06363201Not applicable
- Risk Adapted Therapy of Hodgkin Lymphoma in Upper EgyptNot yet recruitingNCT06340243
- The Pathogenesis and Prognostic Factors of LymphomaRecruitingNCT06203652
- BV-AVD-R Treatment Children Hodgkin's LymphomaEnrolling by invitationNCT06201507Phase 2
- Azacitidine Plus PD-1 Therapy for R/R Hodgkin LymphomaRecruitingNCT06190067Phase 2
- Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasRecruitingNCT06176690Phase 1
- A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)RecruitingNCT06170489Phase 3
- A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesRecruitingNCT06150664Phase 1
- AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.RecruitingNCT06137144Phase 1/2
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a SolutionRecruitingNCT06131801
- Hodgkin's Disease and Chemotherapy Before 40 YearsNot yet recruitingNCT06116929Not applicable
- Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)RecruitingNCT06098430
- ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 CellsRecruitingNCT06090864Phase 1/2
- CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantRecruitingNCT06059391Phase 2
- Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin LymphomaNot yet recruitingNCT06045195Phase 2
- Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline ChemotherapyRecruitingNCT05977673Phase 2
- Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer PatientsAvailableNCT05974410
- A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's LymphomaRecruitingNCT05900765Phase 2
- SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT05896046Phase 1/2
- Lifestyle Intervention of Food and Exercise for Lymphoma SurvivorsRecruitingNCT05839210Not applicable
- Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant DiseasesRecruitingNCT05800210Phase 2
- Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory LymphomaRecruitingNCT05798897Phase 1
- Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin LymphomaRecruitingNCT05757466Phase 2
- Early Detection and Screening of Hematological Malignancies - SANGUINERecruitingNCT05735704
- Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's LymphomaEnrolling by invitationNCT05683704Phase 2
- Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphomaNot yet recruitingNCT05627115Phase 2
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLRecruitingNCT05615636Phase 2
- Treatment Strategy for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT05595447Phase 2/3
- Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic MalignanciesRecruitingNCT05544968Phase 1
- GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)Not yet recruitingNCT05518318Phase 3
- A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin LymphomaRecruitingNCT05481437
- A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's LymphomaRecruitingNCT05355051Phase 2
- Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaRecruitingNCT05272384Phase 1
- A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's LymphomaRecruitingNCT05244642Phase 3
- Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's LymphomaRecruitingNCT05243693Phase 2
- Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT05180097Phase 2
- A Study of Brentuximab Vedotin in Adults With Hodgkin's LymphomaRecruitingNCT05100056
- Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesRecruitingNCT05092451Phase 1/2
- Two Step Haplo With Radiation ConditioningRecruitingNCT05031897Phase 2
- Faecal Microbiota Transplantation After Allogeneic Stem Cell TransplantationRecruitingNCT04935684Phase 2
- Methods of T Cell Depletion Trial (MoTD)RecruitingNCT04888741Phase 2
- Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin LymphomaRecruitingNCT04871607Phase 2
- Radiation Free Chemotherapy for Early Hodgkin LymphomaRecruitingNCT04866654Phase 2
- A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CTRecruitingNCT04843267Phase 2
- Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT04838652Phase 2
- Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin LymphomaRecruitingNCT04837859Phase 2
- RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCTRecruitingNCT04776265
- Brentuximab Vedotin in Early Stage Hodgkin LymphomaRecruitingNCT04685616Phase 3